ビーゲン社のPD-1阻害薬ティスレリズマブ、日本で承認取得 グローバル製薬大手に挑む
BeiGene's Japanese approval signals that Chinese biotech companies can now compete in the world's most demanding regulatory markets, challenging the dominance of Western pharma giants.
BeiGene received regulatory approval from Japan's MHLW for its PD-1 inhibitor tislelizumab to treat non-small cell lung cancer, marking its entry into the Japanese market.
百济神州的抗 PD-1 抗体替雷利珠单抗获得日本厚生劳动省批准，用于治疗非小细胞肺癌。
BeiGene's Japanese approval signals that Chinese biotech companies can now compete in the world's most demanding regulatory markets, challenging the dominance of Western pharma giants.
Where this signal fits in the broader landscape.
BeiGene、2025年第4四半期および通期決算を発表
BeOne Medicines、2025年第4四半期および通期決算を発表
BeOne Medicines、2025年第4四半期および通期決算を発表へ
BeiGene社、ソノロトクラックスが再発・難治性マントル細胞リンパ腫（R/R MCL）で世界初の承認を取得
ソンロトクラックス、再発・難治性MCLおよび再発・難治性CLL/SLLで世界初の承認を取得
https://pj.jiho.jp/article/253329
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
ログイン